Drug Trial Radar · NCT00268216
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,228
Actual
Start
Sep 2000
Primary completion
Nov 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Salmeterol 50mcg/ Fluticasone Propionate 500mcgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- All cause mortality at 3 years
Locations
459 sites in 44 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Jasper, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Ozark, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Berkeley, California
GSK Investigational Site
Burbank, California
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Fresno, California
GSK Investigational Site
Fullerton, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Rancho Mirage, California
GSK Investigational Site
Riverside, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Francisco, California
GSK Investigational Site
San Luis Obispo, California
GSK Investigational Site
Sepuldeva, California
GSK Investigational Site
Stockton, California
GSK Investigational Site
Sunnyvale, California
GSK Investigational Site
Sylmar, California
GSK Investigational Site
Vista, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Arvada, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Fort Collins, Colorado
GSK Investigational Site
Longmont, Colorado
GSK Investigational Site
Loveland, Colorado
GSK Investigational Site
Pueblo, Colorado
GSK Investigational Site
Wheat Ridge, Colorado
Showing 40 of 459 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.